ZKN-013 is under clinical development by Almirall and currently in Phase I for Epidermolysis Bullosa. According to GlobalData, Phase I drugs for Epidermolysis Bullosa have a 96% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how ZKN-013’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

ZKN-013 overview

ZKN-013 is under development for the treatment of recessive dystrophic epidermolysis bullosa, junctional epidermolysis bullosa (RDEB and JEB), cystic fibrosis and familial adenomatous polyposis. It is administered through oral route. The drug candidate acts by targeting collagen alpha 1 (COL7A1) and adenomatous polyposis coli protein (APC) and is being developed based on TURBO-ZM technology.

Almirall overview

Almirall is a specialty pharmaceutical company that researches, develops, manufactures, and commercializes proprietary medicines and licensed products. The company’s major area of focus is dermatology covering psoriasis, eczema, psoriasis, oncodermatology, onychomicosis, actinic keratosis, acne and other skin infections. It also develops products for autoimmune diseases including rheumatoid arthritis and multiple sclerosis; and gastrointestinal diseases including irritable bowel syndrome with constipation. The company also works together with small and medium-sized companies and healthcare professionals to develop medical solutions and provide them to patients. It operates through affiliates in Europe and Central America and has R&D centers in Spain and Germany. Almirall is headquartered in Barcelona, Spain.

For a complete picture of ZKN-013’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.